Management of CNV in PXE involves the prompt use of intravitreal anti-VEGF injections and vitrectomy with tissue plasminogen activator (tPA) for controlling CNV activity and submacular hemorrhage. This evidence concerns the gene VEGFA and pseudoxanthoma elasticum (inherited or acquired).